Checkpoint Therapeutics (Checkpoint Therapeutics) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Checkpoint Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Checkpoint Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Checkpoint Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Checkpoint Therapeutics's Cash-to-Debt or its related term are showing as below:

CKPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 20.43 Med: No Debt Max: No Debt
Current: No Debt

During the past 9 years, Checkpoint Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 20.43. And the median was No Debt.

CKPT's Cash-to-Debt is ranked better than
99.74% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs CKPT: No Debt

Checkpoint Therapeutics Cash-to-Debt Historical Data

The historical data trend for Checkpoint Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Checkpoint Therapeutics Cash-to-Debt Chart

Checkpoint Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Checkpoint Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Checkpoint Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Checkpoint Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Checkpoint Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkpoint Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Checkpoint Therapeutics's Cash-to-Debt falls into.

Checkpoint Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Checkpoint Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Checkpoint Therapeutics had no debt ⁽¹⁾.

Checkpoint Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Checkpoint Therapeutics had no debt ⁽¹⁾.

Checkpoint Therapeutics (NAS:CKPT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Checkpoint Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Checkpoint Therapeutics (Checkpoint Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (NAS:CKPT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

CZTA:Germany CZTA:Germany

Address

95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453

Website

https://www.checkpointtx.com

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in us. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

Executives

William Garrett Gray	officer: See Remarks	2 GANSEVOORT STREET,, 9TH FLOOR, NEW YORK NY 10014
Oliviero James F Iii	director, officer: CEO, President and Director	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Fortress Biotech, Inc.	10 percent owner	1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Michael S Weiss	director	750 LEXINGTON AVE, NEW YORK NY 10022
Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Christian Bechon	director	C/O LFB, 3, AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91940
Barry M Salzman	director	464 COMMON STREET, SUITE 301, BELMONT MA 02478
Scott Boilen	director	2 SKYLINE DRIVE, HAWTHORNE NY 10532
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
David J Horin	officer: Interim CFO	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020